Introduction
Cancer patients are faced with a range of disease-and treatment-related effects that might alter metabolism, food intake and body composition and cause significant physical and psychosocial impairment. Physical exercise has in general a positive impact on many biological processes such as energy expenditure, insulin resistance, inflammation and most body organs and tissues. In cancer patients, there is evidence that physical exercise contributes to reduce fatigue [1] , improves quality of life [2, 3] and relieves many of the adverse side-effects experienced both during and after treatment [4, 5] .
Physical exercise is defined as an activity that is planned, structured, repetitive and purposeful, with the aim to improve or maintain one or more components of physical fitness i.e. endurance, muscular strength and body composition [6] . According to national and international physical activity recommendations, 150 minutes of weekly moderate intensity aerobic exercise, or alternatively 75 minutes of high-intensity exercise, are required to promote and maintain health in adults. Additionally, muscle-strengthening exercise is recommended to be performed twice weekly [7] .
In principle, the same activity recommendations apply to patients with cancer [8] . However, a range of factors beyond those usually encountered when providing exercise advice in healthy populations must be considered, especially in patients who are undergoing cancer treatment or experience adverse side-effects of treatment [9, 10] . Physical exercise is considered to be welltolerated, feasible and safe during and following cancer treatment [5, 11] and even cancer patients with advanced stages of disease are willing to engage in physical exercise [12] . Thus, based on current knowledge, it is considered clinically sound to advise most cancer patient to perform physical exercise.
Cancer cachexia is "a multifactorial condition characterised by an on-going loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment" [13] . As much as 60 -80 % of patients with advanced cancer, depending on diagnosis, develop this condition and at present there are few efficient therapeutic options [14] . Physical exercise may be of particular importance for cancer patients with advanced disease in a pre-cachectic or cachectic stage because of its potential effects on muscle mass and strength [15] . Experimental trials have demonstrated possible anti-inflammatory effects of exercise in cachectic mice [16] as well as partial rescue of muscle mass and strength in tumour -bearing mice when exercise was combined with eicosapentiaenoic acid [17] . Furthermore, a small number of clinical studies have demonstrated the contribution of exercise to reduce or delay cachexia in patients with chronic diseases other than cancer [18, 19] . Previous reviews on effects of physical exercise in patients with cachexia have been narrative and not specific to cancer patients [20, 21] , or have mainly discussed biological and pathophysiological effects of exercise on cachexiarelated muscle wasting [22, 23] .
Primarily, our idea for a systematic review was to examine the scientific evidence of effects of physical exercise on muscle mass and strength in cancer patients in a pre-cachectic or cachectic stage.
Our first systematic search, per January 2012, did not identity controlled studies to answer this question, and therefore we re-defined our aims to include a wider group of cancer patients. We consider it appropriate to guide further clinical studies in patients with advanced cancer by extrapolating data from general cancer.
The overall aim of this systematic review was to evaluate the scientific evidence of effect of physical exercise on muscle mass and strength in patients with cancer. The following research questions were formulated:
1. What type of physical exercise intervention i.e. aerobic, resistance or combined aerobic and resistance exercise, is most effective on muscle mass and strength?
2. Is the effect on muscle mass and strength consistent between different cancer patient cohorts with different diagnoses and stage of disease?
Methods

Search strategy and selection criteria
Electronic searches were performed on January of included studies and relevant systematic reviews were reviewed.
The searches consisted of combinations of controlled terminology and free-text terms expressing the concepts; (1) physical exercise, (2) cancer and (3) muscle mass and strength (including terms such as cachexia, anorexia, malnutrition, wasting, and asthenia), and were adapted to each database (PubMed search details in Table 1 ).
To be eligible for inclusion, studies should 1) include patients aged 18 years or more with a confirmed cancer diagnosis and who were about to start or undergoing active cancer treatment at trial entry, 2) physical exercise had to be repetitive (more than once), consist of aerobic 1 or strength exercise 2 or a combination of both, and be delivered either as a single intervention or as part of a multimodal approach and finally 3) published in a peer reviewed journals and written in English language.
Trial selection and data extraction
All identified records were screened for duplicates and irrelevant titles by the first author (GBS) and one of the co-authors (IIR). Remaining abstracts were screened by two reviewers (GBS, LMO) and subsequently full-text papers were reviewed independently in pairs of two and two reviewers (GBS, LMO, TRB, JLH). In both instances, cases of disagreement about eligibility between two reviewers warranted a third reviewer's opinion.
Eligible studies were then submitted to data extraction using a custom made pre-piloted electronic form using a Microsoft Office Excel 2010 software spread sheet. Data on study design, participants, interventions, outcome measures, results and conclusions were extracted independently by two reviewers. Disagreements on final inclusion and exclusion were resolved by consensus by two of the authors (GBS, LMO).
Assessment of study limitations
All included studies were subject to an assessment of study quality performed independently by two reviewers. The assessment was based on the criteria for "risk of bias" within the GRADE system for rating quality of evidence [24] . These criteria are: randomisation procedures, allocation concealment, blinding, power-estimation, loss to follow-up, intention-to-treat analysis and selective end-point reporting. Study limitations for each trial were summarized in a table and described in the text.
Data synthesis
In the included trials treatment effects for each of the two or more groups are presented as differences in change between the groups. In order to compare effects across studies and outcomes (muscle strength and muscle mass) effect sizes were calculated according to Cohen's method [25] . Standardised mean difference (SMD) was calculated based on descriptive data (mean, standard deviation) at postintervention and sample sizes for each trial. The formula for SMD is: mean values for experimental group minus mean values for control group divided by the pooled 3 standard deviation [26] . The SMD and the 95 % confidence intervals are presented in the text. According to Cohen's "rule of thumb" a SMD of 0.2-0.5 is considered small to moderate, 0.51 -0.8 moderate to large and greater than 0.8 large [25] .
Results
Search results and selection of studies
The database searches retrieved 1321 records which were reduced to 405 after removal of duplicates and exclusion of irrelevant records by title. After screening of abstracts, 76 records were found to meet the inclusion criteria. Furthermore, nine records were identified by manual searches, giving 85 full text publications to be screened for eligibility. Out of these, 67 papers did not meet the selection criteria and were excluded. Thus, data extraction was performed on 18 papers. Two of the papers were publications based on the same study and were excluded [27, 28] , leaving 16 trials for final synthesis. Figure 1 shows the outcome of the search process and selection of studies.
Ten trials compared one physical exercise regime against usual care (UC [41] . One trial compared RE alone or together with a low fat vegetable diet against a control group. All groups in this trial received calcium-rich diet [42] . Details of the content of the physical exercise programs are provided in Table 2 .
Effects on muscle mass
Detailed results on muscle mass are presented in Table 3 . Two trials reported better effect on muscle mass for patients randomised to CAE compared with UC. In Battaglini and colleagues [31] , the CAE group (exercise three days per week for six weeks) increased their lean body mass (LBM) compared to patients in the UC group ( 3.1 % ↑ versus 0.2 % ↓; p=0.004). In Coleman and colleagues [32] , the CAE group (exercise two days per week for eight weeks) increased LBM while the UC group lost LBM (0.4 % ↑versus 0.4 % ↓; p<0.01).
In a study by Courneya and colleagues [37] No effects were reported in the trials by Cunningham and colleagues [41] , comparing two RE groups exercising three or five days per week with UC, the study by Mustian and colleagues [34] comparing a CAE group exercising seven days a week for four weeks with UC, or in the trial by
Demark-Wahnefried and colleagues [42] comparing three groups: calcium-rich diet only, calciumrich diet + RE and calcium rich + RE + low fat vegetable diet. In the latter study, patients in the RE groups exercised five days a week for 26 weeks.
Effect sizes could be calculated for two studies using Dual Energy X-ray Analysis (DEXA) as outcome. In the study by Courneya and colleagues [37] the post-treatment effect was better for RE than UC however the effect was small (SMD = 0.22; CI -0.1 to 0.6). There was no additional effect of AE compared with UC. In the study by Demark-Wahnefried et al [42] , a small to moderate effect size was found in favour of the UC (receiving calcium rich diet only) compared with the two experimental groups I) calcium rich diet + RE (SMD = 0. 27; CI -2.9 to 2.2) and II) calcium rich diet + RE + low-fat vegetable diet (SMD= 0.36; CI -2.8 to 2.3).
Effect on muscle strength
Details on results on muscle strength are provided in [36] .
Three trials reported that RE was better than UC in improving muscle strength. In Courneya and colleagues [37] , patients in the RE group exercised three days per week for 17 weeks (chest press: 3.3 kg ↑ versus 1.5 kg ↑; p<0.001 and leg press: 8.2 kg ↑ versus 1.4 kg ↑; p=0.001). In a trial by Segal and colleagues [40] , patients in the RE group exercised three days a week for 24 weeks (chest press: 10.9 kg ↑ versus 2.5. kg ↓; p<0.001 and leg press 25.6 kg ↑ versus 0.4 kg ↑; p<0.001). In the two trials by Schwartz et al [38, 39] , better effects for RE than UC was only reported in the most recent study [38] for 1RM overhead press (1.3 kg ↑ versus 0.9 kg ↓; p<0.05), seated row (31.7 kg ↑ versus 1.4 kg ↓; p<0.05) and for leg extension (21.1 kg ↑ versus 1.8 kg ↑; p<0.05).
Better effects of AE than UC on muscle strength was reported in five studies; Baumann and colleagues [29] for isometric quadriceps muscle strength (10 % ↓ versus 24 % ↓; p=0.002); Monga and colleagues [43] for time to complete a five repetition sit to stand test ( For AE, moderate to large effect sizes were found in the two trials by Schwartz and colleagues [38, 39] for overhead press (SMD 0.7; CI -0. Effect sizes in favour of AE compared to UC were small in two trials by Courneya and colleagues [37] and Segal and colleagues [40] for the outcomes chest press (SMD 0.0; CI -0. Effect sizes were moderate to small both for upper and lower body strength in favour of CAE compared with UC in three trials [30, 33, 36] . Effect sizes were largest in the study by Jarden and colleagues [33] for both leg extension (SMD 1.7; CI -3.5 to 6.9) and chest press (0.8; CI -5.5 to 7.1).
More moderate effects were found by Adamsen and colleagues [30] for leg extension (0.5; CI 0.3 to 0.8) and chest press (0.3; CI 0.1 to 0.6) and by Wiskemann and colleagues [36] for isometric strength in upper body (SMD 0.2; CI -0.3 to 0.6) and lower body (SMD 0.3; CI -0.1 to 0.8).
For grip strength (not illustrated in Figure 2 ) effect sizes were small in favour of CAE versus UC (SMD = 0.23; CI -0.5 to 0.1) [35] .
Comparing effects across patient cohorts
The majority of trials were performed on stage I-III breast cancer patients undergoing adjuvant chemotherapy and prostate cancer patients receiving radiation therapy. A few trials included some other cancer diagnoses, such as bowel or colon cancer [30, 31, 34, 37-40, 42, 43] . Six trials included patients with various haematological malignancies, mainly acute or chronic leukaemia or lymphomas, undergoing hematopoietic stem cell transplants (HSCT) [29, 33, 36, 41] . Only one trial included patients with advanced stage IV cancer undergoing palliative cancer treatment. These patients were diagnosed with tumours in the gastro-intestinal tract, breast, lung or bladder [35] .
Muscle mass was reported in only six trials, and except for two trials involving HSCT patients [32, 41] , these were conducted on patients with breast cancer or prostate cancer [31, 34, 37, 42] . Overall, the tendency in these six trials was that the experimental groups (either AE, RE or CAE) maintained or modestly improved muscle mass from pre to post-test while the CG reduced muscle mass.
For muscle strength outcomes, moderate to large effects were demonstrated in the trials on breast and prostate cancer patients [30, 31, [37] [38] [39] [40] and in trials on HSCT patients [29, 32, 33, 36] but not in patients with advanced stage IV cancer [35] , where effects on grip strength were small.
Study limitations (risk of bias)
The quality assessment of the included trials is provided in Table 5 .
Nine trials described methods used for random allocation. Six trials used concealed allocation [31-34, 37, 40, 41] . The majority of trials had small sample sizes; eight trials had less than 50
participants [29, 31-34, 41, 43, 44] . Four trials were feasibility trials [29, 32, 34, 42] .
Overall, the most frequent study limitation was lack of blinding of assessors. In only two trials blinding was applied [34, 40] . Six trials had drop-out rates above > 20% [29, 32, 35, 36, 41, 44] . In case of three of these trials, it was not reported how missing data were dealt with [32, 41, 44] . Nine of the trials reported data analysis by using intention-to-treat principles [29, 30, 32-36, 38, 40] .
The majority of trials described one primary outcome, which was muscle mass or muscle strength in only two trials [31, 44] .
Outcome measurements
Six trials used muscle mass as an outcome. Two trials measured muscle mass as Lean body Mass (LBM) using a Skinfold Calliper, in which one expressed LBM in percentage [31] and the other as arm muscle area (mm 2 ) [41] . Two trials measured LBM, expressed as kilograms, using Dual X-ray Absorptiometry [37, 42] . One trial measured LBM in kilograms by using Air Displacement
Plethysmography [32] . Finally, one trial measured skeletal muscle mass (kg) using Bioelectrical Impedance Analysis [34] .
Fourteen trials had muscle strength as an outcome. Estimations of one repetition maximum (1RM) for upper and lower body strength were most frequently used [30] [31] [32] [33] [37] [38] [39] [40] . Chest press (involving major muscles of the chest, shoulders and triceps), seated row (involving the Lattisimus Dorsi and the Rhomboid muscles, predominantly) and leg extension (involving all major leg muscle groups such as Quadriceps, Hamstrings and Gluteus maximum), were most commonly used.
Maximum isometric strength was measured in four trials [29, 33, 36, 44] , grip strength by dynamometry in two trials [34, 35] , and a functional test to assess leg strength in one trial [43] . Except for the functional strength test (sit-to-stand measured in seconds), all trials reported muscle strength in kilograms or Newton (1 kg equals 9.81 N).
Discussion
Summary of results
In this systematic review of 16 trials with cancer patients during active treatment, both aerobic and resistance exercise, and a combination of these, improves upper and lower body muscle strength more than usual care. Muscle mass was reported in only six trials and shows a tendency towards an effect of physical exercise on maintaining muscle mass during treatment. There are some indications that resistance exercise (RE) is more effective than aerobic exercise (AE) both on muscle mass and strength, though the evidence is not very strong. Large effects on muscle strength were demonstrated across different patient cohorts. However, most trials involved patients with early stage cancer while only one trial was on patients with advanced cancer.
Effects of physical exercise
This review shows a possible effect of physical exercise on muscle mass during cancer treatment, as three trials reported significantly better effects of physical exercise compared to usual care [31, 32, 37] .
The findings are in line with a systematic review and a meta-analysis by Speck et al [5] based on five trials reporting muscle mass as outcome. This review concluded with small effects sizes in favour of different physical activity interventions compared with usual care in cancer survivors. One of the trials by Demark-Wahnefried et al [42] included in the present review reported negative findings for resistance training and low fat diet on LBM compared to usual care. The negative result can likely be explained by a higher non-adherence rate in the experimental groups. In summary, because of few exercise trials using muscle mass as outcome, most of them having methodological shortcomings, there is still too little evidence to draw a firm conclusion on the effect of physical exercise on muscle mass for patients undergoing cancer treatment.
The present review of 14 trials using muscle strength as outcome, demonstrated a positive effect of physical exercise compared to usual care. These findings are also in line with Speck and colleagues [5] who, based on eight trials, concluded with small to moderate effect of physical exercise on muscle strength.
From the review, as compared to UC, we found positive effects of exercise on muscle strength in favour of AE in five trials [29, [38] [39] [40] 43] ; RE in three trials [37, 38, 40] and CAE in four trials [30, 31, 33, 35] . Only two trials compared effects of AE and RE, and both reported significantly better effect of RE on change in muscle strength [37, 40] . Furthermore, the study by Courneya and colleagues from 2007 [37] also found a significant effect in favour of RE compared to AE on muscle mass. Although the evidence is not very strong, the result could support the use of RE in future clinical trials.
Populations
The majority of trials in the present review included breast or prostate cancer patients. Only three trials included patient groups with other types of solid tumors, such as gastro-intestinal, bowel or lung cancer [30, 35, 39] . Possible explanations for this are that recruitment into exercise trials in very sick patients is challenging due to a high disease and symptom burden, side-effect of treatment, and gatekeeping from health personnel. [45] This review found six trials conducted in patients with hematological malignances undergoing hematopoietic stem cell transplant (HSCT) and high dose chemotherapy, and only one trial [35] conducted in cancer patients with advanced disease. Muscle wasting is a common symptom, reported in more than 60 % of patients with advanced cancer [14] and patients with hematological malignancies undergoing stem cell transplants [46] . For both groups there is a need for treatment strategies that contribute to reduce side-effect of treatment, maintain muscle mass and strength in order to maintain quality of life, and prolong survival. Future exercise trials are therefore needed in cancer populations at high risk for developing cachexia.
Even if the search criteria were set to detect papers with patients prone to cachexia, the present review only identified one trial with advanced cancer patients. In this study, patients with advanced incurable cancer were randomized to eight weeks of CAE performed twice weekly in a supervised hospital setting, or to usual care. The increased grip strength in the CAE relative to UC supports previous uncontrolled trials in advanced cancer [47, 48] on efficacy of exercise on muscle strength also in this population. In conclusion, the findings from our review support the effect of exercise on muscle strength in cancer patient undergoing curative treatment. The evidence is however sparse with regards to the effects in patients with advanced cancer.
Methodological quality of the included trials
Conclusions that can be drawn from any literature review are based on the quality of the trials included. Thus, identifying possible biases in the conducted trials are essential [24] . The included trials in the present review had some shortcomings: First, the trials varied considerably in terms of sample size. Eight trials had less than 50 participants [31-34, 39, 41, 43, 44] , and only one of performed a sample size estimation [33] . Second, nine trials lacked or did not report use of concealed allocation [29, 30, 35, 36, 38, 39, [42] [43] [44] . Third, in most trials, the assessment and interventions was performed by the same persons.
Outcomes
Previous reviews on effects of physical exercise in patients with cachexia have been narrative and not been specific to cancer patients [20, 21] or have mainly discussed biological and pathophysiological aspects of exercise on cachexia-related muscle wasting [22, 23] . Existing systematic reviews and meta-analyses on the effects of physical exercise in cancer patients have evaluated multiple end-points both during and after anti-cancer treatment [5, 49] , and many have primarily focused on specific outcomes such as fatigue [1] and quality of life [3] . At present, no systematic review has primarily been designed to examine the effect of physical exercise on muscle mass and strength in cancer patients during active treatment. Considering that depletion of muscle mass is associated with more toxic side-effects, poor response of cancer treatment and short survival in advanced cancer populations, muscle mass as outcome should be of clinical interest. Furthermore, preventing loss of muscle mass and function during active cancer treatment may contribute to maintaining activities of daily living. In advanced cancer patients, reduction in daily physical activity is linked to impaired quality of life [50] . Further trials are needed to assess the effect of exercise on muscle mass and secondary on quality of life in these patients.
Several factors are to be considered when using muscle mass as endpoint. Precise measurements of skeletal muscle mass require expensive equipment and experienced personnel that might not always be a feasible option in a clinical research setting. In addition, the type and dose of exercise required to gain muscle mass remains unclear, making it difficult to interpret what are clinically relevant changes in muscle mass following exercise interventions. Further trials should also assess whether muscle strength can be used as a surrogate outcome for muscle mass in clinical trials in advanced cancer patients.
Study limitations
The search strategy in this systematic review was pre-defined and designed by a trained research librarian and performed in multiple biomedical and therapeutic databases in order to reduce publication bias. A large group of different search terms were used to represent muscle outcomes as well as cachexia however it was acknowledged that search terms for outcomes are not always represented in abstracts of indexing terms (i.e. Mesh). To account for this, additional manual searches were performed by the first author (GBS) in bibliographies of the 85 full-text articles.
Although we searched for trials of relevance for patients with cachexia, only one RCT conducted in patients with advanced stage cancer was detected. As only RCT's were included, two uncontrolled trials performed in patients with advanced lung cancer [47, 48] were not described in our results. These trials showed improvement in muscle strength after eight weeks of CAE but none of these studies used muscle mass as outcome. Furthermore, an observational study of a multimodal rehabilitation intervention (nutrition, exercise and symptom management) involving cancer patients with advanced disease and significant anorexia/weight loss, was identified but not included [51] . After two months of intervention, patients who were still in the study increased their body weight and physical function, and reduced their symptom burden. This is the only study identified through the literature search that provides data concerning physical exercise in cancer cachexia. However, a few study protocols of ongoing trials were identified [52, 53] ; suggesting that the research focus in this field will increase in the time to come.
Conclusion and future directions
This systematic review provides evidence that both aerobic and resistance exercise or a combination of these, can contribute to improve muscle strength more than usual care in cancer patients during treatment. Whether these different types of exercise have specific effects remains unclear.
Improvements in muscle mass were demonstrated in favor of resistance exercise; however the evidence was not strong. Few trials measured muscle mass and besides one large trial; the studies included a small number of patients. Although effects were similar across different patients cohorts included in this review, there was a predominance of trials conducted in patients with early stage cancer, and conclusions cannot be drawn with regard to advanced cancer populations. Future research in this field should include studies of effects of physical exercise on muscle mass in patients with advanced cancer and at risk of cancer cachexia.
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Technology in Trondheim. No statistically significant differences in muscle mass between groups at posttreatment. At post-test, there was a statistically significant difference between groups in favor of resistance exercise versus control for chest press (mean difference 7,7 kg; p=0,001) and leg extension (mean difference 6,8 kg; p=0,001) There were no statistically significant difference between the groups aerobic and control. Knee extension -Exp. group 2,2 % increase ( Δ 4,0±1,5 to 4,1± 1,6) -control 20,1 % decrease ( Δ 3,9±1,5 to 3,1±1,2); p<0,0001 Statistical significant differences between groups in change in muscle strength was found in favor of exp. group versus control group for chest press (p < 0,001), leg extension (p=0,0003), elbow flexion (p=0,0009) and knee extension (p<0,0001) In exp. group, there were no statistically significant changes in upper body muscle strength but for control group, muscle strength was significantly reduced in all muscle groups, except dominant elbow extensors For lower body muscle strength, significant reductions were found for the exp. group in dominant (p=0,033) and non-dominant (p=0,0001) knee flexors, The control group significantly reduced lower body muscle strength in knee flexors (p<0,01), ankle flexors (p<0,01) There were statically significant differences between groups at post -test in favor of exp. group versus control group for non-dominant hip-flexors (p<0,01) There were no statistically significant differences in muscle strength between groups at post intervention, Effect sizes for muscle strength, measured in kilograms, for physical exercise including a) combined aerobic and strength exercise, b) aerobic exercise alone and c) strength exercise alone. The bars illustrate the standardised mean difference (dots) and the upper and lower 95 % confidence intervals for each outcome (upper body and lower body strength measured as kilograms) in the presented studies (n=7)*. Effect sizes above zero represent the magnitude of the effect in favour of physical exercise compared to treatment as usual. Effect sizes < 0.2 are interpreted as small; 0.2 -0.5 small to moderate; 0.51 -0.8 moderate to large; >0.8 large.
Monga
* Out of 12 studies measuring muscle strength, 7 studies using repetition maximum or isometric testing is reported in figure. 4 studies measuring muscle strength as a sum
